IS7097A - Medicinal product for the administration of intramuscular filvestrant - Google Patents

Medicinal product for the administration of intramuscular filvestrant

Info

Publication number
IS7097A
IS7097A IS7097A IS7097A IS7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A
Authority
IS
Iceland
Prior art keywords
filvestrant
intramuscular
administration
medicinal product
medicinal
Prior art date
Application number
IS7097A
Other languages
Icelandic (is)
Inventor
Kay Cahill Julie
Richard Gellert Paul
Marshall Irving Alan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7097A publication Critical patent/IS7097A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IS7097A 2001-07-07 2004-01-05 Medicinal product for the administration of intramuscular filvestrant IS7097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (1)

Publication Number Publication Date
IS7097A true IS7097A (en) 2004-01-05

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7097A IS7097A (en) 2001-07-07 2004-01-05 Medicinal product for the administration of intramuscular filvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (en)
JP (1) JP2004534093A (en)
CN (1) CN1553815A (en)
AR (1) AR037138A1 (en)
BR (1) BR0210898A (en)
CA (1) CA2453111A1 (en)
CO (1) CO5560585A2 (en)
HU (1) HUP0400115A3 (en)
IL (1) IL159576A0 (en)
IS (1) IS7097A (en)
MX (1) MXPA04000028A (en)
NO (1) NO20040047L (en)
PL (1) PL367624A1 (en)
RU (1) RU2004102393A (en)
WO (1) WO2003006064A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2011022861A1 (en) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600064A (en) * 2012-03-31 2012-07-25 西安力邦制药有限公司 Fulvestrant or fulvestrant derivative sustained release preparation and preparation method thereof
CN102600073B (en) 2012-03-31 2014-01-01 莱普德制药有限公司 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method of oily preparation
CN102600065B (en) * 2012-03-31 2014-08-13 莱普德制药有限公司 Fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2017175810A1 (en) * 2016-04-06 2017-10-12 富士フイルム株式会社 Medicinal composition
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of using them
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2017208847A1 (en) 2016-05-31 2017-12-07 富士フイルム株式会社 Pharmaceutical composition
MX2020004792A (en) 2017-11-08 2020-08-13 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use.
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
EP3747442B1 (en) * 2018-01-31 2024-07-10 FUJIFILM Corporation Method for producing preparation for injection
CN111481559B (en) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 High-concentration fulvestrant composition and preparation method thereof
EP4074304A4 (en) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
JP2024545690A (en) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション Pharmaceutical composition of fulvestrant with improved solubility and its preparation method
CN118717660B (en) * 2024-06-12 2025-02-28 湖州亚瑟制药有限公司 Fulvestrant pharmaceutical composition for injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
RU2004102393A (en) 2005-03-27
HUP0400115A3 (en) 2005-11-28
BR0210898A (en) 2004-06-22
MXPA04000028A (en) 2004-05-21
CA2453111A1 (en) 2003-01-23
CN1553815A (en) 2004-12-08
AR037138A1 (en) 2004-10-27
NO20040047L (en) 2004-02-23
CO5560585A2 (en) 2005-09-30
IL159576A0 (en) 2004-06-01
PL367624A1 (en) 2005-03-07
WO2003006064A1 (en) 2003-01-23
EP1406662A1 (en) 2004-04-14
HUP0400115A2 (en) 2004-06-28
JP2004534093A (en) 2004-11-11

Similar Documents

Publication Publication Date Title
NO20033384D0 (en) Pharmaceutical formulation
IS6994A (en) Aripiprazole solution for oral administration
NO20033785D0 (en) Pharmaceutical formulation
IS6986A (en) Liquid pharmaceutical composition
NO20033556D0 (en) Pharmaceutical preparations
DE60220661D1 (en) TRANSDERMALES PLASTER FOR THE ADMINISTRATION OF FENTANYL
FI20011478A0 (en) Pharmaceutical composition
ITTO20010008A0 (en) PHARMACEUTICAL FORMULATION
IS7097A (en) Medicinal product for the administration of intramuscular filvestrant
EE05020B1 (en) The pharmaceutical composition of G1buride
NO20035627D0 (en) Pharmaceutical formulation
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
EE200300589A (en) Pharmaceutical compositions
DE60203537D1 (en) 5HT1-RECEPTORAGONIST-CONTAINING MEDICAMENT
NO20040860L (en) Pharmaceutical composition including lumiracoxib
NO20034556D0 (en) Imidazotriazinone-containing compositions for nasal administration
NO20041485L (en) Pharmaceutical formulation comprising (R) -bicalutamide
DK1475379T3 (en) Use of scopin ester derivatives for the manufacture of drugs
NO20042640L (en) Process for the preparation of echinocandin derivatives
NO20023445D0 (en) Process for the preparation of peptides
DK1385512T3 (en) Use of pyridoindolone derivatives for the preparation of anticancer drugs
FI20010892A0 (en) Process for the preparation of xylitol
FI20012242A0 (en) New pharmaceutical compounds
NO20041236L (en) Pharmaceutical Formulation
NO20040312L (en) Process for the preparation of pharmaceutical preparations